David Jakeman Sells 2,800 Shares of Chimerix, Inc. (NASDAQ:CMRX) Stock

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) VP David Jakeman sold 2,800 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $4.10, for a total transaction of $11,480.00. Following the sale, the vice president now owns 149,287 shares of the company's stock, valued at $612,076.70. This trade represents a 1.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Chimerix Stock Up 3.4 %

NASDAQ CMRX traded up $0.13 during trading hours on Tuesday, hitting $3.93. 881,610 shares of the stock were exchanged, compared to its average volume of 1,405,028. The company has a market cap of $353.46 million, a price-to-earnings ratio of -4.18 and a beta of 0.35. Chimerix, Inc. has a 12-month low of $0.75 and a 12-month high of $4.22. The stock has a 50-day moving average of $2.98 and a 200 day moving average of $1.64.

Chimerix (NASDAQ:CMRX - Get Free Report) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.26 million. During the same period last year, the business posted ($0.27) earnings per share. On average, equities research analysts expect that Chimerix, Inc. will post -0.99 earnings per share for the current year.

Analyst Ratings Changes

CMRX has been the subject of a number of recent research reports. Wedbush reaffirmed an "outperform" rating and set a $6.00 price objective on shares of Chimerix in a research report on Tuesday, December 10th. HC Wainwright reaffirmed a "buy" rating and set a $11.00 price target on shares of Chimerix in a report on Monday, December 30th.

Institutional Investors Weigh In On Chimerix

A number of hedge funds and other institutional investors have recently bought and sold shares of CMRX. Valeo Financial Advisors LLC increased its holdings in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 69,505 shares in the last quarter. Marshall Wace LLP acquired a new position in Chimerix during the second quarter worth about $137,000. Stoneridge Investment Partners LLC increased its holdings in Chimerix by 22.5% in the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock valued at $154,000 after buying an additional 8,134 shares in the last quarter. Palumbo Wealth Management LLC acquired a new stake in shares of Chimerix during the 4th quarter valued at approximately $221,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock worth $321,000 after acquiring an additional 138,098 shares in the last quarter. Institutional investors and hedge funds own 45.42% of the company's stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.